Crispr Therapeutics AG (CRSP : NASDAQ)
Common Stock
$53.39
USD
+2.95 (5.85%)
Last updated: 2026-10-09
Follow CRSP
CRSP
Crispr Therapeutics AG
WealthAwesomePerformance
1 Day
+5.85%
1 Week
-3.68%
1 Month
-0.11%
YTD
+0.57%
Key Statistics
Market Cap
$5.16B
52W High
$75.06
52W Low
$44.12
P/E Ratio
-
50 Day MA
$54.99
200 Day MA
$53.23
Beta
1.76
Dividend Yield
-
Advertisement
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 10/9/2026 | $50.82 | $54.07 | $50.52 | $53.39 | $53.39 | 1,465,700 |
| 10/8/2026 | $51.51 | $53.54 | $50.02 | $50.44 | $50.44 | 2,858,774 |
| 10/7/2026 | $53.00 | $54.59 | $52.27 | $52.35 | $52.35 | 1,677,775 |
| 10/6/2026 | $60.38 | $60.68 | $53.74 | $54.00 | $54.00 | 2,616,521 |
| 10/5/2026 | $55.21 | $57.46 | $54.01 | $57.34 | $57.34 | 1,698,652 |
| 10/2/2026 | $56.45 | $57.58 | $54.09 | $55.43 | $55.43 | 1,128,300 |
| 10/1/2026 | $55.45 | $56.59 | $54.82 | $55.44 | $55.44 | 1,058,271 |
| 9/30/2026 | $56.55 | $57.11 | $55.28 | $55.32 | $55.32 | 1,164,584 |
| 9/29/2026 | $54.08 | $56.48 | $54.00 | $56.00 | $56.00 | 1,575,193 |
| 9/28/2026 | $53.84 | $55.63 | $52.90 | $54.09 | $54.09 | 1,269,365 |
Analyst Price Targets
Based on 22 analysts covering CRSP · as of Oct 12, 2026
Wall Street analysts forecast CRSP stock price to rise 63.9% over the next 12 months.
Consensus
Buy3.95 / 5.00
Avg. Target
US$87.50
+63.9% Upside
Previously US$87.56 on Oct 5, 2026
Current Price
US$53.39
Last close
Analyst Breakdown (22 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on CRSP's historical volatility
30-Day Vol
50.3%
Annualized
90-Day Vol
52.6%
Annualized
Trend (90d)
+39.7%
Annualized drift
90d Mean
US$61.53
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$55.98 | US$47.06 – US$66.58 |
| 60 trading days | US$58.69 | US$45.92 – US$75.01 |
| 90 trading days | US$61.53 | US$45.56 – US$83.10 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Crispr Therapeutics AG
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting allogeneic chimeric antigen receptor T cell for autoimmune indications and oncology. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting cluster of differentiation 19 (CD19) and CTX131 targeting CD70 for oncology and autoimmune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
Financials
- Revenue (TTM)
- $13.39M
- EBITDA
- $-513.17M
- Profit Margin
- 0.00%
- ROE (TTM)
- -26.10%
- EPS (Diluted)
- -4.74
- Book Value
- 18.07
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Advertisement
Common Questions About CRSP.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| DFLI | Dragonfly Energy Holdings Corp. | $3.72 | +658.88% |
| WFF | WF Holding Limited Ordinary Shares | $12.29 | +499.51% |
| ILLR | Triller Group Inc. Common Stock | $0.08 | +100.97% |
| JZ | Jianzhi Education Technology Group Company Limited American Depositary Shares | $1.28 | +53.48% |
| ZYBT | Zhengye Biotechnology Holding Limited Ordinary Shares | $1.73 | +50.45% |
| VEEA | Veea Inc. | $5.70 | +47.29% |
| QETA | Quetta Acquisition Corporation Common Stock | $16.41 | +41.47% |
| PDSB | PDS Biotechnology Corp | $1.38 | +35.29% |
CRSP.US news timeline
1 article covering CRSP.US, most recent first
Latest